Susquehanna Maintains Negative on RXO, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 57.2%

Neg 0% Neu 0% Pos 57.2%

Susquehanna analyst Bascome Majors maintains RXO (NYSE:RXO) with a Negative and raises the price target from $18 to $20.